- Page 1 and 2: Tuberculosis Interventions Interven
- Page 3 and 4: Editor International Union Against
- Page 5 and 6: Isoniazid plus rifampicin plus pyra
- Page 7 and 8: 4. Preventive chemotherapy . . . .
- Page 10: Acknowledgments It would not have b
- Page 13 and 14: This monograph deals with the fourt
- Page 15 and 16: ���� �������
- Page 17 and 18: �������� �� �
- Page 19 and 20: contraceptives and anti-retroviral
- Page 21 and 22: is scant. However, the limited evid
- Page 24 and 25: 1. Chemotherapy The primary interve
- Page 26 and 27: ability of the drug in the serum of
- Page 28 and 29: emain elusive, 47 the general mecha
- Page 30 and 31: �����������
- Page 32 and 33: Idiosyncratic reactions from isonia
- Page 34 and 35: tis risk per 1,000 subjects was zer
- Page 36 and 37: �� ��� �� ���
- Page 38 and 39: ���� ����� ��
- Page 40 and 41: ����� ����� �
- Page 42 and 43: Rifampicin may rarely cause pseudom
- Page 44 and 45: • opioids; 292-294 • vitamin K
- Page 46 and 47: Table 4. Summary of adverse reactio
- Page 48 and 49: ����� ������
- Page 52 and 53: orne out by experiments which have
- Page 54 and 55: longed respiratory depression follo
- Page 56 and 57: quent adverse drug events are gastr
- Page 58 and 59: ������ �� ���
- Page 60 and 61: Table 9. Grading of activities of a
- Page 62 and 63: ������ �� ���
- Page 64 and 65: Effective or functional monotherapy
- Page 66 and 67: ���� ����� ��
- Page 68 and 69: drugs with a high therapeutic margi
- Page 70 and 71: Council 122 or the individual trial
- Page 72 and 73: article. The experiences in Edinbur
- Page 74 and 75: Per cent positive 100 80 60 40 20 0
- Page 76 and 77: Based on evidence that the addition
- Page 78 and 79: esented a major advance in research
- Page 80 and 81: cipal consideration is the prevaili
- Page 82 and 83: of six months’ duration with ison
- Page 84 and 85: Treatment efficacy As enteropathy i
- Page 86 and 87: Influence of isoniazid resistance o
- Page 88 and 89: • Patients with sputum smear-posi
- Page 90 and 91: medications were taken daily throug
- Page 92 and 93: of the disease, as alternative drug
- Page 94 and 95: Number of cases per 100,000 populat
- Page 96 and 97: number of cases, the health care pr
- Page 98 and 99: necessary). If the event occurs in
- Page 100 and 101:
The patient with acute renal toxici
- Page 102:
and no association with diarrhea. 5
- Page 105 and 106:
Schools Contacts of new cases Conta
- Page 107 and 108:
too small to allow a meaningful int
- Page 109 and 110:
Cases per 1,000 140 120 100 80 60 4
- Page 111 and 112:
Pasteur, 1921 Moreau, 1924 Tokyo, 1
- Page 113 and 114:
mendation by WHO states that no pri
- Page 115 and 116:
the number of person-years of obser
- Page 117 and 118:
• protection afforded by vaccinat
- Page 119 and 120:
Saskatchewan Saskatchewan Chicago C
- Page 121 and 122:
Three retrospective studies among c
- Page 123 and 124:
Harm / protection (%) 20 0 -20 -40
- Page 125 and 126:
• Differences in virulence of M.
- Page 127 and 128:
infected persons may thus mask any
- Page 129 and 130:
If environmental mycobacteria do in
- Page 131 and 132:
Relative risk (log scale) 10 3 1 0.
- Page 133 and 134:
Because BCG vaccination is given ea
- Page 135 and 136:
the largest purchaser in the world)
- Page 137 and 138:
made here to provide a comprehensiv
- Page 139 and 140:
year following commencement of trea
- Page 141 and 142:
might be expected, therefore, that
- Page 143 and 144:
tionally considered to belong to gr
- Page 145 and 146:
Prevention of disease following ces
- Page 147 and 148:
����� ��� ���
- Page 149 and 150:
��� ���� �� �
- Page 151 and 152:
� �� � ���� ��
- Page 153 and 154:
Table 11. Preventive therapy - effe
- Page 155 and 156:
Logistical problems may, however, i
- Page 157 and 158:
In an uncontrolled study in Zambia,
- Page 159 and 160:
In none of the nine prospective tri
- Page 161 and 162:
is not usually an option, this is t
- Page 163 and 164:
Like other aminoglycosides, amikaci
- Page 165 and 166:
twice rather than once per day, red
- Page 167 and 168:
Quinolones Quinolones have a potent
- Page 169 and 170:
Rifapentine Rifapentine (cyclopenty
- Page 171 and 172:
published a scientific blueprint fo
- Page 173 and 174:
to that of isoniazid. 1162 It appea
- Page 176 and 177:
Appendix 3 Current vaccine developm
- Page 178:
this type of vaccine may not only p
- Page 181 and 182:
15. Goldman AL, Braman SS. Chest 19
- Page 183 and 184:
44. Heym B, Alzari PM, Honoré N, C
- Page 185 and 186:
76. McCurdy PR, Donohoe RF. Pyridox
- Page 187 and 188:
112. Van den Brande P, van Steenber
- Page 189 and 190:
147. Murray FJ. Outbreak of unexpec
- Page 191 and 192:
183. Acocella G, Conti R, Luisetti
- Page 193 and 194:
215. Prazuck T, Fisch A, Simonnet F
- Page 195 and 196:
248. Powell-Jackson PR, Jamieson AP
- Page 197 and 198:
281. LeBel M, Masson E, Guilbert E,
- Page 199 and 200:
310. Yeager RL, Munroe WGC, Dessau
- Page 201 and 202:
341. Crowle AJ, Sbarbaro JA, Judson
- Page 203 and 204:
376. Graham SM, Daley HM, Salanipon
- Page 205 and 206:
410. Paradelis AG, Triantaphyllidis
- Page 207 and 208:
443. Nunn P, Kibuga D, Gathua S, Br
- Page 209 and 210:
471. Mitchison DA. Basic mechanisms
- Page 211 and 212:
501. East African / British Medical
- Page 213 and 214:
526. East African / British Medical
- Page 215 and 216:
554. Medical Research Council. Five
- Page 217 and 218:
580. Nolan CM. Failure of therapy f
- Page 219 and 220:
606. Crofton J, Chaulet P, Maher D,
- Page 221 and 222:
631. Weis SE, Slocum PC, Blais FX,
- Page 223 and 224:
662. Griffith AS. A study of the BC
- Page 225 and 226:
695. Horwitz O, Meyer J. The safety
- Page 227 and 228:
723. World Health Organization. Rec
- Page 229 and 230:
756. Al-Kassimi FA, Al-Hajjaj MS, A
- Page 231 and 232:
785. Comstock GW, Webster RG. Tuber
- Page 233 and 234:
814. Vynnycky E, Fine PEM. The annu
- Page 235 and 236:
843. Talic RF, Hargreve TB, Bishop
- Page 237 and 238:
871. Pamra SP, Mathur GP. Effects o
- Page 239 and 240:
897. American Thoracic Society, Cen
- Page 241 and 242:
924. Elliott AM, Halwiindi B, Bagsh
- Page 243 and 244:
957. Escobar JA, Belsey MA, Dueñas
- Page 245 and 246:
989. Hoffner SE, Källenius G. Susc
- Page 247 and 248:
1021. Helmy B. 220-5. Side effects
- Page 249 and 250:
1053. Thomas L, Naumann P, Crea A.
- Page 251 and 252:
1083. Perumal VK, Gangadharam PRJ,
- Page 253 and 254:
1109. Lucchesi M. L’éthionamide
- Page 255 and 256:
1141. Ashtekar DR, Costa-Perira R,
- Page 257 and 258:
1165. Oleksijew A, Meulbroek J, Ewi
- Page 259 and 260:
1193. Hondalus MK, Bardarov S, Russ
- Page 262:
IMPRESSION, BROCHAGE IMPRIMERIE CHI